Pharmacy

Entry of generics post March 2026, patient dropouts to affect sales values, say experts

The company sharpens its domestic specialty formulations focus and looks to scale APIs through acquisitions, while planning partnership-led GLP-1 launches

Ozempic, a once-weekly injectable approved by the US Food and Drug Administration in 2017 for type 2 diabetes, has become a global bestseller and is widely used off-label for weight los

Apollo Pharmacy has crossed the 7,000-store milestone and now plans to open two new outlets every day for five years, expanding its reach through physical stores and its Apollo 24|7 digital platform

Apollo Pharmacy plans to open two new stores every day, targeting to grow its customer base to 10 crore within the next five years, its CEO P Jayakumar said on Friday. The omni-channel pharmacy network, which has crossed the 7,000-store mark with the opening of its latest store in Ayodhya, Uttar Pradesh, aims to strengthen the neighbourhood pharmacy reach. "We will continue to expand by opening two new stores every day and grow our customer base to 100 million within the next five years, ensuring that the highest-quality medicines remain within everyone's reach," Jayakumar said in a statement. Apollo HealthCo operates Apollo Pharmacy that serves users across over 19,000 pin codes. Apollo HealthCo Executive Chairperson Shobana Kamineni said at present, Apollo Pharmacy serves over one million orders every day. "The 7,000-store milestone reflects the scale Apollo has built and the trust families place in us. We will continue to deepen access, strengthen India's neighbourhood pharmacy

Apollo Hospitals CFO says the restructuring and listing of its digital and pharmacy businesses will be completed by the last quarter of FY27, after approvals from regulators including SEBI and NCLT.

Quick commerce platform Zepto on Thursday announced its entry into the online pharmacy segment with the launch of 'Zepto Pharmacy', promising medicine delivery within 10 minutes in select metropolitan areas. The service has been rolled out in specific locations across Mumbai, Bengaluru, Delhi-NCR, and Hyderabad, Zepto Co-Founder and CEO Aadit Palicha said in a post on LinkedIn. The launch follows a 12-month pilot phase focused on refining operations, he said. "Today, we're formally announcing the launch of Zepto Pharmacy - Medicines delivered in 10 minutes! Over the past 12 months, the team has worked tirelessly to perfect the customer experience, supply chain, and compliance at a small scale, and we want to grow it steadily from here. Our objective is to keep operational standards extremely high and not scale too rapidly, given the complexity of this category," he wrote. The move marks Zepto's expansion beyond its core 10-minute grocery delivery model, placing it in competition wi

Despite flat volumes, India's pharma market posted 7.9% growth in July on strong demand for chronic therapies like cardiac and diabetes; MAT turnover crossed Rs 2.3 trillion

JM Financial initiated coverage on Emcure Pharma with a 'Buy' rating and a target price of ₹1,740, citing its growth prospects

To prevent misuse of Schedule H, H1, and X drugs, the Delhi government directs all chemist shops to install CCTV cameras by July 31; the move follows 11th National Narcotics Coordination Portal meetin

A preliminary enquiry by the CBI pointed to suspected manipulation in the inspection and recognition processes for pharmacy colleges across several states, PTI reported

Medical device companies raise issues with the DoP over UDMPMD norms related to disclosure of training expenses and restrictions on overseas training approvals

SastaSundar Ventures Ltd is in the process of investing Rs 150 crore over the next two years to strengthen its digital healthcare platform and warehousing infrastructure to make a turnaround and return to profit in FY'26, a company official said on Thursday. The investment will largely be funded through a Rs 145-crore capital pool, created from the Flipkart Health exit settlement and internal treasury income. The Kolkata-based online pharmacy ended its partnership with Flipkart Health earlier this year and relaunched its B2C platform under its own brand. "We are aiming to return to net profit in the current fiscal through strategic initiatives. We are focusing on the execution of these and capital-efficient growth to recover the company from a Rs 122 crore net loss in FY'25. "Out of the Rs 150 crore, about Rs 40 crore was deployed in FY'25, and the remaining Rs 110 crore will be invested in FY'26 and FY'27," SastaSundar Chairman B L Mittal told PTI. To tap into the rising demand f

Andhra University has released the Andhra Pradesh Post Graduate Engineering Common Entrance Test (AP PGECET) 2025 answer key today at 4 pm. Candidates can check it at cets.apsche.ap.gov.in/PGECET

Sun Pharmaceutical Industries has lined up a USD 100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 million. Elaborating

Zydus Wellness Ltd on Monday reported a 14.4 per cent rise in consolidated net profit at Rs 171.9 crore in the fourth quarter ended March 31, 2025, driven by strong performance of its food and nutrition as well as personal care segments. The company had posted a consolidated net profit of Rs 150.3 crore in the same quarter of the previous fiscal. The board of the company has approved the sub-division of its stock with one equity share of face value of Rs 10 to be split into five equity shares of face value Rs 2 each, subject to shareholders' approval. Consolidated total revenue from operations in the fourth quarter stood at Rs 910.6 crore, as compared to Rs 778 crore in the year-ago period, Zydus Wellness Ltd said in a regulatory filing. Total expenses in the quarter under review were higher at Rs 740.5 crore, as compared to Rs 632.2 crore in the corresponding period a year ago. With the continued thrust on marketing initiatives, several key brands including Nutralite, Glucon-D, .

Agriculture, pharma, electronics, and engineering goods together accounted for over 50 per cent of India's merchandise exports in 2024-25, according to government data, highlighting the country's growing strength in diverse sectors amid efforts to boost manufacturing and value-added exports. Engineering goods contributed the highest share of 26.67 per cent to India's USD 437.42 billion exports in 2024-25, while agriculture, pharmaceuticals, and electronics accounted for 11.85 per cent, 6.96 per cent, and 8.82 per cent, respectively. The data showed that the electronic goods sector saw the highest export growth rate at 32.46 per cent, jumping from USD 29.12 billion in 2023-24 to USD 38.58 billion in the last fiscal year. It was USD 23.6 billion in 2022-23 and USD 15.7 billion in 2021-22. Within this, computer hardware and peripherals, which form 3.8 per cent of the sector, saw 101 per cent growth, doubling from USD 0.7 billion to USD 1.4 billion. The main destinations for electronic

IPA and Ind-Ra say Trump's MFN-based drug pricing move will impact innovators more than Indian generics, with CDMO firms likely to gain from offshore cost advantages

Commerce and Industry Minister Piyush Goyal on Saturday emphasised on the crucial role of innovation in driving the growth of the Indian pharmaceutical industry and warned that without innovation, the industry will be "finished". He also expressed concern that the industry often relies on government incentives to conduct research and development in the sector. "Sadly, our country's mindset has become so weak that for everything we are looking up to the government... we think that only after getting a tax incentive then only we will do research. This is the industry where innovation determines success, whoever will not innovate will be finished," he said, while addressing members of the drug making firms in Mumbai. He also cautioned that if the industry will not innovate, its future is worrisome. The industry will have to keep pace with the changing lifestyle patterns besides demands and needs of the society and patents, Goyal said. He called upon the industry to come forward with

White-collar hiring activities in January witnessed 4 per cent growth driven by traditional sectors, including FMCG, pharma and insurance, according to a report released on Monday. "In 2024, January had greeted us with a disappointing 11 per cent de-growth in hiring. In contrast, 2025 seems to have started on a positive note. The 4 per cent hiring growth is tempered as IT recovery settles in, however, strong growth in most core sectors, including FMCG, pharma, insurance and hospitality is a good sign and augurs well for a cracking 2025 in terms of white collar hiring," Naukri Chief Business Officer Pawan Goyal said in a statement quoting NaukriJobSpeak Index. The report revealed a steady hiring environment with strong performances in core sectors like FMCG (16 per cent), insurance (15 per cent), and pharma (11 per cent), and hospitality by 8 per cent, while IT hiring remained flattish, the report added. The Naukri JobSpeak is a monthly index representing the Indian job market and ..